TD Cowen reduced its target price and maintained a 'buy' rating for Abbott Laboratories, while the company also filed 13F reports with the SEC.
1 report, 1 independent
Updated Jun 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen reduced its target price and maintained a 'buy' rating for Abbott Laboratories, while the company also filed 13F reports with the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Abbott Laboratories
American global health care and medical device products company
-
TD Cowen
American investment bank
Related events
- FirstCash received price target and rating upgrades from TD Cowen, filed 13F with the SEC, and traded on Nasdaq.
- TD Cowen, Jefferies, and Citigroup issued updated ratings and target prices for Procore Technologies, Inc.
- Rating firms Raymond James Financial and TD Cowen provided reaffirmed buy ratings and price targets for a company listed on Nasdaq.
- TD Cowen, Morgan Stanley, and other firms issued various ratings and price targets for Circle Internet Group on August 27, 2026.
- Financial firms, including TD Cowen and Morgan Stanley, raised target prices and issued buy ratings for Permian Resources.